3-nitropropionic acid has been researched along with Nerve Degeneration in 71 studies
3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE
3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Multiple system atrophy (MSA) is a progressive neurodegenerative disease characterized by autonomic failure, parkinsonism, cerebellar ataxia, and oligodendrocytic accumulation of alpha-synuclein (alphasyn)." | 7.75 | Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. ( Adame, A; Inglis, C; Lee, PH; Mante, M; Masliah, E; Rockenstein, E; Stefanova, N; Ubhi, K; Wenning, GK, 2009) |
| "Multiple system atrophy (MSA) is a progressive neurodegenerative disease characterized by autonomic failure, parkinsonism, cerebellar ataxia, and oligodendrocytic accumulation of alpha-synuclein (alphasyn)." | 3.75 | Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. ( Adame, A; Inglis, C; Lee, PH; Mante, M; Masliah, E; Rockenstein, E; Stefanova, N; Ubhi, K; Wenning, GK, 2009) |
| "Atorvastatin-treated rats showed fewer neurologic deficits than control animals as measured at day 3-5." | 1.35 | Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways. ( Chu, K; Han, Z; Hong, NH; Im, WS; Jung, KH; Kang, L; Kim, M; Kim, MW; Lee, ST; Park, JE, 2008) |
| " It is known that dopamine (DA) enhances this toxic effect." | 1.35 | Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production. ( Cano, J; de Pablos, RM; Herrera, AJ; Machado, A; Navarro, A; Santiago, M; Tomás-Camardiel, M; Villarán, RF, 2008) |
| "However, its potential in Huntington's disease (HD) models characterized by calpain-dependent degeneration and inflammation has not been investigated." | 1.33 | Minocycline in phenotypic models of Huntington's disease. ( Bantubungi, K; Blum, D; Brotchi, J; Brouillet, E; Chtarto, A; Déglon, N; Galas, MC; Greco, A; Jacquard, C; Levivier, M; Minghetti, L; Pintor, A; Popoli, P; Schiffmann, SN; Tai, K; Tenenbaum, L, 2005) |
| " These results indicate that antagonists of NMDA-type glutamate receptors are protective during the toxic outcome associated with mitochondrial dysfunction." | 1.33 | 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism. ( Bahr, BA; Baude, AS; Brown, QB; Karanian, DA; Parsons, CG, 2006) |
| "Huntington's disease has an increase in the activated calpain, which is enhanced by the NMDA receptor activation." | 1.33 | Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. ( Chu, K; Jung, KH; Kang, L; Kim, M; Ko, SY; Lee, ST; Park, JE, 2006) |
| "An important aspect of Huntington's disease (HD) pathogenesis which may have important therapeutic implications is that the cellular events leading to cell death may be different in cortical and striatal neurons." | 1.32 | Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. ( Bantubungi, K; Bizat, N; Blum, D; Brouillet, E; Cuvelier, L; Galas, MC; Schiffmann, SN, 2004) |
| "We developed a primate model of striatonigral degeneration (SND), the neuropathology underlying levodopa-unresponsive parkinsonism associated with multiple systemic atrophy (MSA-P), by sequential systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3-nitropropionic acid (3NP) in a Macaca fascicularis monkey." | 1.31 | Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. ( Aubert, I; Bezard, E; Fernagut, PO; Ghorayeb, I; Poewe, W; Tison, F; Wenning, GK, 2000) |
| "Manganese (Mn) in excess is toxic to neurons of the globus pallidus, leading to a Parkinsonian-like syndrome." | 1.31 | Manganese toxicity is associated with mitochondrial dysfunction and DNA fragmentation in rat primary striatal neurons. ( Malecki, EA, 2001) |
| "Cotreatment with riluzole (4 mg/kg i." | 1.30 | Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. ( Brouillet, E; Guyot, MC; Hantraye, P; Mary, V; Palfi, S; Peschanski, M; Riche, D; Stutzmann, JM; Wahl, F, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (23.94) | 18.2507 |
| 2000's | 42 (59.15) | 29.6817 |
| 2010's | 11 (15.49) | 24.3611 |
| 2020's | 1 (1.41) | 2.80 |
| Authors | Studies |
|---|---|
| Ranganayaki, S | 1 |
| Govindaraj, P | 1 |
| Gayathri, N | 1 |
| Srinivas Bharath, MM | 1 |
| Li, Y | 1 |
| Sheng, Y | 1 |
| Liang, JM | 1 |
| Hu, J | 1 |
| Ren, XY | 1 |
| Cheng, Y | 1 |
| Ahmed, LA | 1 |
| Darwish, HA | 1 |
| Abdelsalam, RM | 1 |
| Amin, HA | 1 |
| Gopinath, K | 1 |
| Sudhandiran, G | 1 |
| Thangarajan, S | 1 |
| Ramachandran, S | 1 |
| Krishnamurthy, P | 1 |
| Malik, J | 1 |
| Karan, M | 1 |
| Dogra, R | 1 |
| Nasr, P | 1 |
| Carbery, T | 1 |
| Geddes, JW | 2 |
| Pelegrí, C | 3 |
| Duran-Vilaregut, J | 3 |
| del Valle, J | 3 |
| Crespo-Biel, N | 1 |
| Ferrer, I | 1 |
| Pallàs, M | 4 |
| Camins, A | 4 |
| Vilaplana, J | 3 |
| Park, JE | 3 |
| Lee, ST | 3 |
| Im, WS | 2 |
| Chu, K | 3 |
| Kim, M | 3 |
| Ubhi, K | 1 |
| Lee, PH | 1 |
| Adame, A | 1 |
| Inglis, C | 1 |
| Mante, M | 1 |
| Rockenstein, E | 1 |
| Stefanova, N | 1 |
| Wenning, GK | 2 |
| Masliah, E | 1 |
| Pandey, M | 1 |
| Borah, A | 1 |
| Varghese, M | 1 |
| Barman, PK | 1 |
| Mohanakumar, KP | 1 |
| Usha, R | 1 |
| Brunet, N | 1 |
| Tarabal, O | 1 |
| Esquerda, JE | 1 |
| Calderó, J | 1 |
| Lagoa, R | 1 |
| Lopez-Sanchez, C | 1 |
| Samhan-Arias, AK | 1 |
| Gañan, CM | 1 |
| Garcia-Martinez, V | 1 |
| Gutierrez-Merino, C | 1 |
| Mizutari, K | 1 |
| Fujioka, M | 1 |
| Nakagawa, S | 1 |
| Fujii, M | 1 |
| Ogawa, K | 1 |
| Matsunaga, T | 1 |
| Manich, G | 2 |
| Junyent, F | 2 |
| Binienda, ZK | 1 |
| Beaudoin, MA | 1 |
| Gough, B | 1 |
| Ali, SF | 2 |
| Virmani, A | 2 |
| Mu, S | 1 |
| OuYang, L | 1 |
| Liu, B | 1 |
| Zhu, Y | 1 |
| Li, K | 1 |
| Zhan, M | 1 |
| Liu, Z | 1 |
| Jia, Y | 1 |
| Lei, W | 1 |
| Reiner, A | 1 |
| de Lemos, L | 1 |
| Verdaguer, E | 1 |
| Folch, J | 1 |
| Beas-Zárate, C | 1 |
| Auladell, C | 1 |
| Vis, JC | 1 |
| de Boer-van Huizen, RT | 1 |
| Verbeek, MM | 1 |
| de Waal, RM | 1 |
| ten Donkelaar, HJ | 1 |
| Kremer, B | 1 |
| Hanbury, R | 1 |
| Chen, EY | 1 |
| Wuu, J | 1 |
| Kordower, JH | 2 |
| Saydoff, JA | 1 |
| Liu, LS | 1 |
| Garcia, RA | 1 |
| Hu, Z | 1 |
| Li, D | 1 |
| von Borstel, RW | 1 |
| Galas, MC | 4 |
| Bizat, N | 4 |
| Cuvelier, L | 2 |
| Bantubungi, K | 2 |
| Brouillet, E | 7 |
| Schiffmann, SN | 4 |
| Blum, D | 5 |
| Saulle, E | 1 |
| Gubellini, P | 1 |
| Picconi, B | 2 |
| Centonze, D | 1 |
| Tropepi, D | 1 |
| Pisani, A | 2 |
| Morari, M | 1 |
| Marti, M | 1 |
| Rossi, L | 1 |
| Papa, M | 1 |
| Bernardi, G | 2 |
| Calabresi, P | 2 |
| Diguet, E | 2 |
| Fernagut, PO | 3 |
| Wei, X | 1 |
| Du, Y | 1 |
| Rouland, R | 1 |
| Gross, C | 1 |
| Bezard, E | 2 |
| Tison, F | 3 |
| Binienda, Z | 3 |
| Przybyla-Zawislak, B | 1 |
| Schmued, L | 2 |
| Hemming, FJ | 1 |
| Torch, S | 1 |
| Sadoul, R | 1 |
| Almeida, S | 1 |
| Domingues, A | 1 |
| Rodrigues, L | 1 |
| Oliveira, CR | 1 |
| Rego, AC | 1 |
| Jacquard, C | 3 |
| Greco, A | 1 |
| Pintor, A | 1 |
| Chtarto, A | 1 |
| Tai, K | 1 |
| Tenenbaum, L | 1 |
| Déglon, N | 1 |
| Popoli, P | 1 |
| Minghetti, L | 1 |
| Brotchi, J | 1 |
| Levivier, M | 1 |
| Schmued, LC | 2 |
| Stowers, CC | 1 |
| Scallet, AC | 2 |
| Xu, L | 1 |
| Nam, E | 1 |
| Lee, SM | 1 |
| Koh, SE | 1 |
| Joo, WS | 1 |
| Maeng, S | 1 |
| Im, HI | 1 |
| Kim, YS | 1 |
| Boyer, F | 1 |
| Hermel, JM | 1 |
| Hantraye, P | 4 |
| Ueberham, U | 1 |
| Ueberham, E | 1 |
| Brückner, MK | 1 |
| Seeger, G | 1 |
| Gärtner, U | 1 |
| Gruschka, H | 1 |
| Gebhardt, R | 1 |
| Arendt, T | 1 |
| Tariq, M | 1 |
| Khan, HA | 1 |
| Elfaki, I | 1 |
| Al Deeb, S | 1 |
| Al Moutaery, K | 1 |
| Passino, E | 1 |
| Sgobio, C | 1 |
| Bonsi, P | 1 |
| Barone, I | 1 |
| Ghiglieri, V | 1 |
| Ammassari-Teule, M | 1 |
| Túnez, I | 1 |
| Collado, JA | 1 |
| Medina, FJ | 1 |
| Peña, J | 1 |
| Del C Muñoz, M | 1 |
| Jimena, I | 1 |
| Franco, F | 1 |
| Rueda, I | 1 |
| Feijóo, M | 1 |
| Muntané, J | 1 |
| Montilla, P | 1 |
| Karanian, DA | 1 |
| Baude, AS | 1 |
| Brown, QB | 1 |
| Parsons, CG | 1 |
| Bahr, BA | 1 |
| Kang, L | 2 |
| Ko, SY | 1 |
| Jung, KH | 2 |
| Ramaswamy, S | 1 |
| McBride, JL | 1 |
| Herzog, CD | 1 |
| Brandon, E | 1 |
| Gasmi, M | 1 |
| Bartus, RT | 1 |
| Huang, QY | 1 |
| Yu, L | 1 |
| Ferrante, RJ | 2 |
| Chen, JF | 1 |
| Hong, NH | 1 |
| Han, Z | 1 |
| Kim, MW | 1 |
| Villarán, RF | 1 |
| Tomás-Camardiel, M | 1 |
| de Pablos, RM | 1 |
| Santiago, M | 1 |
| Herrera, AJ | 1 |
| Navarro, A | 1 |
| Machado, A | 1 |
| Cano, J | 1 |
| Silva-Adaya, D | 1 |
| Pérez-De La Cruz, V | 1 |
| Herrera-Mundo, MN | 1 |
| Mendoza-Macedo, K | 1 |
| Villeda-Hernández, J | 1 |
| Santamaría, A | 1 |
| Nishino, H | 2 |
| Shimano, Y | 1 |
| Kumazaki, M | 1 |
| Sakurai, T | 1 |
| Riepe, M | 1 |
| Ludolph, A | 1 |
| Seelig, M | 2 |
| Spencer, PS | 2 |
| Ludolph, AC | 2 |
| Frim, DM | 1 |
| Simpson, J | 1 |
| Uhler, TA | 1 |
| Short, MP | 1 |
| Bossi, SR | 1 |
| Breakefield, XO | 1 |
| Isacson, O | 1 |
| Bowyer, JF | 1 |
| Clausing, P | 1 |
| Davies, DL | 1 |
| Newport, GD | 1 |
| Slikker, W | 2 |
| Albertson, C | 1 |
| Nakao, N | 1 |
| Brundin, P | 1 |
| Palfi, S | 2 |
| Riche, D | 1 |
| Guyot, MC | 2 |
| Mary, V | 1 |
| Wahl, F | 1 |
| Peschanski, M | 1 |
| Stutzmann, JM | 1 |
| Borlongan, CV | 1 |
| Sanberg, PR | 1 |
| Mittoux, V | 2 |
| Altairac, S | 2 |
| Condé, F | 2 |
| Alexi, T | 2 |
| Hughes, PE | 2 |
| Faull, RL | 1 |
| Williams, CE | 1 |
| Knüsel, B | 1 |
| Tobin, AJ | 1 |
| Andreassen, OA | 1 |
| Beal, MF | 1 |
| Jørgensen, HA | 1 |
| Reynolds, DS | 1 |
| Carter, RJ | 1 |
| Morton, AJ | 1 |
| Maragos, WF | 1 |
| Jakel, RJ | 1 |
| Pang, Z | 1 |
| Sánchez-Carbente, MR | 1 |
| Massieu, L | 2 |
| Chyi, T | 1 |
| Chang, C | 2 |
| Ouary, S | 1 |
| Ménétrat, H | 1 |
| Ghorayeb, I | 1 |
| Aubert, I | 1 |
| Poewe, W | 1 |
| Lee, WT | 1 |
| Lee, CS | 1 |
| Pan, YL | 1 |
| Duan, W | 1 |
| Guo, Z | 1 |
| Mattson, MP | 2 |
| Yu, Z | 1 |
| Zhou, D | 1 |
| Cheng, G | 1 |
| Malecki, EA | 1 |
| Keene, CD | 1 |
| Rodrigues, CM | 1 |
| Eich, T | 1 |
| Linehan-Stieers, C | 1 |
| Abt, A | 1 |
| Kren, BT | 1 |
| Steer, CJ | 1 |
| Low, WC | 1 |
| Del Río, P | 1 |
| Montiel, T | 1 |
| Teunissen, CE | 1 |
| Mulder, M | 1 |
| de Vente, J | 1 |
| von Bergmann, K | 1 |
| De Bruijn, C | 1 |
| Steinbusch, HW | 1 |
| Lütjohann, D | 1 |
| Jaber, M | 1 |
| Bioulac, B | 1 |
| Ludolph, AG | 1 |
| Sabri, MI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ursodiol in Huntington's Disease[NCT00514774] | Phase 1 | 21 participants (Anticipated) | Interventional | 2007-08-31 | Active, not recruiting | ||
| A Randomized, Double-blind Multicenter Pilot Study vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis[NCT00877604] | Phase 2 | 34 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Responder patients were defined as those subjects showing an improvement of at least 15% in the ALSFRS-R slope during the treatment period as compared to the lead-in period. (NCT00877604)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| TUDCA | 13 |
| Placebo | 6 |
3 reviews available for 3-nitropropionic acid and Nerve Degeneration
| Article | Year |
|---|---|
3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease.
Topics: Animals; Humans; Huntingtin Protein; Huntington Disease; Mitochondria; Neostriatum; Nerve Degenerati | 2005 |
Systemic, but not intraparenchymal, administration of 3-nitropropionic acid mimics the neuropathology of Huntington's disease: a speculative explanation.
Topics: Animals; Huntington Disease; Injections; Neostriatum; Nerve Degeneration; Neurotoxins; Nitro Compoun | 1997 |
3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration.
Topics: Animals; Basal Ganglia; Central Nervous System; Humans; Nerve Degeneration; Neurotoxins; Nitro Compo | 1998 |
68 other studies available for 3-nitropropionic acid and Nerve Degeneration
| Article | Year |
|---|---|
Exposure to the neurotoxin 3-nitropropionic acid in neuronal cells induces unique histone acetylation pattern: Implications for neurodegeneration.
Topics: Acetylation; Animals; Cell Line; Histones; Nerve Degeneration; Neurons; Nitro Compounds; Propionates | 2020 |
Self-protection of type III fibrocytes against severe 3-nitropropionic-acid-induced cochlear damage in mice.
Topics: Animals; Apoptosis; Aquaporin 1; Caspase 3; Cell Proliferation; Cochlea; Cochlear Diseases; Evoked P | 2018 |
Role of Rho Kinase Inhibition in the Protective Effect of Fasudil and Simvastatin Against 3-Nitropropionic Acid-Induced Striatal Neurodegeneration and Mitochondrial Dysfunction in Rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; bcl-2-Associated X Protein; Behavior, Animal | 2016 |
Protective effect of naringin on 3-nitropropionic acid-induced neurodegeneration through the modulation of matrix metalloproteinases and glial fibrillary acidic protein.
Topics: Animals; Behavior, Animal; Corpus Striatum; Flavanones; Glial Fibrillary Acidic Protein; Inflammatio | 2016 |
Chrysin exerts neuroprotective effects against 3-Nitropropionic acid induced behavioral despair-Mitochondrial dysfunction and striatal apoptosis via upregulating Bcl-2 gene and downregulating Bax-Bad genes in male wistar rats.
Topics: Animals; Apoptosis; Basal Ganglia; bcl-2-Associated X Protein; bcl-Associated Death Protein; Behavio | 2016 |
Ameliorating effect of Celastrus paniculatus standardized extract and its fractions on 3-nitropropionic acid induced neuronal damage in rats: possible antioxidant mechanism.
Topics: Animals; Antioxidants; Behavior, Animal; Biomarkers; Brain; Celastrus; Chromatography, Thin Layer; C | 2017 |
N-methyl-D-aspartate receptor antagonists have variable affect in 3-nitropropionic acid toxicity.
Topics: Adenosine Diphosphate; Animals; Corpus Striatum; Dizocilpine Maleate; Drug Interactions; Male; Meman | 2009 |
Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3-nitropropionic acid.
Topics: Animals; Apoptosis; Cell Cycle Proteins; Convulsants; Corpus Striatum; Cyclin D1; Disease Models, An | 2008 |
Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease.
Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, | 2008 |
Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Brain; Convulsants; Disease Models, Animal; Mice; Mice, Transgenic; Mitoch | 2009 |
Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.
Topics: Animals; Convulsants; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Respo | 2009 |
Excitotoxic motoneuron degeneration induced by glutamate receptor agonists and mitochondrial toxins in organotypic cultures of chick embryo spinal cord.
Topics: Animals; Calcium Signaling; Chick Embryo; Disease Models, Animal; Dose-Response Relationship, Drug; | 2009 |
Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid.
Topics: Animals; Calpain; Caspases; Convulsants; Corpus Striatum; Creatine Kinase; Disease Models, Animal; H | 2009 |
Balance dysfunction resulting from acute inner ear energy failure is caused primarily by vestibular hair cell damage.
Topics: Animals; Caloric Tests; Cochlea; Disease Models, Animal; Dose-Response Relationship, Drug; Hair Cell | 2010 |
Systemic administration of 3-nitropropionic acid points out a different role for active caspase-3 in neurons and astrocytes.
Topics: Animals; Apoptosis; Astrocytes; Caspase 3; Convulsants; Corpus Striatum; Disease Models, Animal; Enz | 2010 |
Assessment of 3-nitropropionic acid-evoked peripheral neuropathy in rats: neuroprotective effects of acetyl-l-carnitine and resveratrol.
Topics: Acetylcarnitine; Animals; Antioxidants; Axons; Environmental Pollutants; Male; Nerve Degeneration; N | 2010 |
Preferential interneuron survival in the transition zone of 3-NP-induced striatal injury in rats.
Topics: Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; Huntington Disease; Interneurons; M | 2011 |
Lack of Jun-N-terminal kinase 3 (JNK3) does not protect against neurodegeneration induced by 3-nitropropionic acid.
Topics: Animals; Blotting, Western; Convulsants; Corpus Striatum; Disease Models, Animal; Enzyme Activation; | 2012 |
Expression pattern of ataxia telangiectasia mutated (ATM), p53, Akt, and glycogen synthase kinase-3β in the striatum of rats treated with 3-nitropropionic acid.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Convulsants; Corpus Striatum; | 2012 |
3-Nitropropionic acid induces cell death and mitochondrial dysfunction in rat corticostriatal slice cultures.
Topics: Animals; Apoptosis; Cerebral Cortex; Convulsants; Corpus Striatum; In Situ Nick-End Labeling; Mitoch | 2002 |
Knockout of p75NTR does not alter the viability of striatal neurons following a metabolic or excitotoxic injury.
Topics: Animals; Astrocytes; Brain Injuries; Cell Death; Cell Survival; Energy Metabolism; Gliosis; Immunohi | 2003 |
Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease.
Topics: Acetates; Administration, Oral; Animals; Huntington Disease; Male; Mice; Mitochondria; Motor Activit | 2003 |
Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms.
Topics: Animals; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-Associated Death Protein; Ca | 2004 |
Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease.
Topics: Acetylcholine; Adenosine Triphosphate; Animals; Cell Respiration; Dose-Response Relationship, Drug; | 2004 |
Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.
Topics: Animals; Cells, Cultured; Convulsants; Corpus Striatum; Disease Models, Animal; Female; Huntington D | 2004 |
Neuroprotective effect of L-carnitine in the 3-nitropropionic acid (3-NPA)-evoked neurotoxicity in rats.
Topics: Animals; Carnitine; Cell Death; Corpus Striatum; Male; Nerve Degeneration; Neuroprotective Agents; N | 2004 |
Increased Alix (apoptosis-linked gene-2 interacting protein X) immunoreactivity in the degenerating striatum of rats chronically treated by 3-nitropropionic acid.
Topics: Animals; Apoptosis; Calcium-Binding Proteins; Carrier Proteins; Corpus Striatum; Immunohistochemistr | 2004 |
FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures.
Topics: Animals; Apoptosis; Caspases; Cell Death; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; | 2004 |
Minocycline in phenotypic models of Huntington's disease.
Topics: Animals; Calpain; Caspases; Cell Death; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Do | 2005 |
Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons.
Topics: Animals; Astrocytes; Brain; Fluoresceins; Fluorescent Dyes; Glial Fibrillary Acidic Protein; Immunoh | 2005 |
Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum.
Topics: Analysis of Variance; Animals; Antioxidants; Cell Death; Corpus Striatum; Lipid Peroxidation; Male; | 2005 |
Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain.
Topics: Animals; Calpain; Carrier Proteins; Cell Death; Huntington Disease; Immunohistochemistry; Injections | 2005 |
Inducible neuronal expression of transgenic TGF-beta1 in vivo: dissection of short-term and long-term effects.
Topics: Animals; Anti-Bacterial Agents; Apolipoproteins E; Benzothiazoles; Brain; Doxycycline; Gene Expressi | 2005 |
Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Down-R | 2005 |
Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons.
Topics: Acetylcholine; Animals; Behavior, Animal; Cholinergic Fibers; Convulsants; Disease Models, Animal; E | 2006 |
17 beta-Estradiol may affect vulnerability of striatum in a 3-nitropropionic acid-induced experimental model of Huntington's disease in ovariectomized rats.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Cell Survival; Convulsants; Corpus Striatum; Cytoprotection | 2006 |
3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism.
Topics: Animals; Animals, Newborn; Cytoskeleton; Dose-Response Relationship, Drug; Excitatory Amino Acid Ant | 2006 |
Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease.
Topics: Animals; Apoptosis Regulatory Proteins; Calpain; Cell Death; Corpus Striatum; Disease Models, Animal | 2006 |
Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
Topics: Animals; Cell Count; Cell Death; Corpus Striatum; Cytoprotection; Dependovirus; Disease Models, Anim | 2007 |
Mutant SOD1G93A in bone marrow-derived cells exacerbates 3-nitropropionic acid induced striatal damage in mice.
Topics: Amyotrophic Lateral Sclerosis; Animals; Bone Marrow Cells; Bone Marrow Transplantation; Corpus Stria | 2007 |
Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways.
Topics: Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Enzyme Activation; Extracellular Sig | 2008 |
Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production.
Topics: alpha-Methyltyrosine; Animals; Apoptosis; Astrocytes; Cell Respiration; Corpus Striatum; Dopamine; D | 2008 |
Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine.
Topics: Animals; Antioxidants; Brain; Carnitine; Convulsants; Disease Models, Animal; Dose-Response Relation | 2008 |
Chronically administered 3-nitropropionic acid induces striatal lesions attributed to dysfunction of the blood-brain barrier.
Topics: Animals; Antihypertensive Agents; Blood-Brain Barrier; Brain Diseases; Complement C3b; Complement C4 | 1995 |
Increase of ATP levels by glutamate antagonists is unrelated to neuroprotection.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Adenosine Triphosphate; Animals; Culture Techniques; Dizocilpi | 1994 |
Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF.
Topics: Acetylcholinesterase; Animals; Brain Tissue Transplantation; Cell Line; Corpus Striatum; Energy Meta | 1993 |
Parenterally administered 3-nitropropionic acid and amphetamine can combine to produce damage to terminals and cell bodies in the striatum.
Topics: Amphetamine; Animals; Behavior, Animal; Biogenic Monoamines; Body Temperature; Central Nervous Syste | 1996 |
Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antihypertensive Agents; Axons; Dizocilpine M | 1997 |
Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid.
Topics: Amphetamine; Animals; Apomorphine; Cell Survival; Cyclic N-Oxides; Dopamine Agonists; Dopamine and c | 1997 |
Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Topics: Acetylcholinesterase; Animals; Antiparkinson Agents; Apomorphine; Caudate Nucleus; Corpus Striatum; | 1997 |
Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat.
Topics: Animals; Brain; Cerebral Cortex; Corpus Striatum; Drug Administration Schedule; Kinetics; Male; Nerv | 1998 |
Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/c ByJ mice.
Topics: Aging; Animals; Apoptosis; Corpus Striatum; DNA Fragmentation; Mice; Mice, Inbred BALB C; Nerve Dege | 1998 |
Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.
Topics: Analysis of Variance; Animals; Anti-Dyskinesia Agents; Antihypertensive Agents; Behavior, Animal; Co | 1998 |
Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzazepines; Corpus Striatum; Disease Models, A | 1998 |
6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions.
Topics: Animals; Antihypertensive Agents; Corpus Striatum; Denervation; Male; Malonates; Mitochondria; Nerve | 1998 |
Transient inhibition of glutamate uptake in vivo induces neurodegeneration when energy metabolism is impaired.
Topics: Animals; Antihypertensive Agents; Aspartic Acid; Biological Transport; Brain Chemistry; Corpus Stria | 1999 |
Temporal evolution of 3-nitropropionic acid-induced neurodegeneration in the rat brain by T2-weighted, diffusion-weighted, and perfusion magnetic resonance imaging.
Topics: Animals; Brain; Cerebrovascular Circulation; Magnetic Resonance Imaging; Male; Nerve Degeneration; N | 1999 |
Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies.
Topics: Animals; Behavior, Animal; Cell Survival; Convulsants; Disease Models, Animal; Drug Administration R | 2000 |
Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus S | 2000 |
Temporal changes of cerebral metabolites and striatal lesions in acute 3-nitropropionic acid intoxication in the rat.
Topics: Acetates; Animals; Aspartic Acid; Cerebrovascular Circulation; Corpus Striatum; Image Processing, Co | 2000 |
Participation of par-4 in the degeneration of striatal neurons induced by metabolic compromise with 3-nitropropionic acid.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carrier Proteins; Caspases; Corpus Striatum; Enzy | 2000 |
Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease.
Topics: Animals; Apoptosis; Calcium; Cell Survival; Cells, Cultured; Convulsants; Disease Models, Animal; Fe | 2000 |
Manganese toxicity is associated with mitochondrial dysfunction and DNA fragmentation in rat primary striatal neurons.
Topics: Animals; Cells, Cultured; Coloring Agents; Convulsants; Corpus Striatum; DNA Fragmentation; Electron | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
Neurotoxicity of glutamate uptake inhibition in vivo: correlation with succinate dehydrogenase activity and prevention by energy substrates.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Amino Acid Transport System X-AG; Animals; Brain Ischemia; Con | 2001 |
Concentrations of different sterols in the striatum and serum of 3-nitropropionic acid-treated Wistar and Lewis rats.
Topics: Animals; Cholesterol; Corpus Striatum; Nerve Degeneration; Neurotoxins; Nitro Compounds; Oxidative S | 2001 |
Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage.
Topics: Animals; Basal Ganglia Diseases; Cell Death; Convulsants; Dopamine; Dopamine Plasma Membrane Transpo | 2002 |
ATP deficits and neuronal degeneration induced by 3-nitropropionic acid.
Topics: Adenosine Triphosphate; Animals; Cerebral Cortex; Dose-Response Relationship, Drug; Fetus; Kinetics; | 1992 |